Terry Smith retweeted
Replying to @silvertrade
I hate to even comment on such a serious thing because only the safety of people matters, but FWIW I asked Teva’s CEO about their operations in Israel earlier this month and he said Israel is less than 8% of their manufacturing. biotechtv.com/post/teva-marc…
Excellent report from Furey research partners. Small cap managers are getting crushed by the outperformance in biotech where they seem to be chronically under-exposed.
1
2
452
This is good news for the Inhibrx CVR (pays $5/unit if this drug is approved by 6/30/27). sanofi.com/en/media-room/pre…
Wow. Interesting use of Twitter by Dr. Makary
This Post is from an account that no longer exists. Learn more
2
1,086
All those companies waiting to submit their NDA until Rare Disease Day just wasted two months.
Replying to @FDA
3
882
Would love to see 75 more of these
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
6
879
Acadia Pharma announced sale of their PRV for $150M. Ipsen got $158M for one in August. Previously the market had been around $100M.
Terry Smith retweeted
$NVS Ronny Gal on factors driving upside and downside in launch expectations by the Street analysts
Super interesting, even though one has to understand more deeply some of these factors (which I’m sure are being investigated further) linkedin.com/posts/ronny-gal…
I'm super late. Anyone worried that the PFS of 8 mos is based on 6 patients at risk with lots of censors at 2-3 mos? It seems they counted unconfirmed responders who are still on drug as responders? I calc ORR on the first 61 pts at 26% and ORR on the next 36 as 11%. Right? $RVMD
9
1,829
Wow, X has informed me that I have been on X for 14 years. For some reason it doesn’t seem that long! #MyXAnniversary
1
6
1,185
Terry Smith retweeted
Excellent results of acoramidis for #ATTR CM in ATTRIBUTE trial, just presented at #ESCCongress @secardiologia @seccCFyGenetCV @UnidadTtr
First quarter of launch Daybue sales $21-$23M.
Guide to $45-55M next Q.
Consensus was $2.5M and $7.2M, respectively.
$ACAD
Very interesting parent feedback. $ACAD facebook.com/groups/11223213…
5
508
Terry Smith retweeted
Pipeline herding in drug development -
In 2000, there were on avg 3 assets/target
In 2022, there are on avg 7 assets/target
(in oncology its 9 assets/target)
nature.com/articles/d41573-0…
Oncology is 37% of the entire biopharma pipeline.
FDA is issuing new draft guidance, "Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics," per Fed Register Public Inspection notice. I don't think the doc is up yet but it should post here fda.gov/regulatory-informati…
FR notice public-inspection.federalreg…
Terry Smith retweeted
Wow. FDA's top cell and gene therapy official is stepping down.
It's a critical time for CGTs at FDA, with the division about to start a hiring spree and OTAT getting a recent reorganization (to the Office of Therapeutic Products).
Director of @FDACBER OTAT Wilson Bryan is retiring. He will leave by the end of March. Big loss for the cell and gene therapy divisions at the agency. #pharma
Is there anything stopping a hedge fund from filing another IPR on voclosporin? $AUPH
1
2
863
Terry Smith retweeted
Got lots of Qs on my FOIA for #biotech post. So here's a 🧵on FOIA document content with an example:





















